Subscribe

Receive the latest news and updates from Cidara.

ContentCategoriesTags

TIMM

Virtual | October 2021
,

IDWeek

Virtual | Sep-Oct 2021

,

The long-acting echinocandin, rezafungin, prevents Pneumocystis pneumonia and eliminates Pneumocystis from the lungs in prophylaxis and murine treatment modelsJ Fungi | September 2021

,

ISICEM

Virtual | August 2021

,

ISHAM-Asia

Virtual | August 2021

,

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections | Antimicrob Agents Chemother | August 2021 | online ahead of print

,

Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report | Open Forum Infect Dis | August 2021

,

ECCMID

Virtual | July 2021

,

Erratum | Clin Infect Dis | June 2021 | online ahead of print

,

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum | Microorganisms | April 2021 | Vol 9, Issue 4

,

ICHS SYMPOSIUM

VIRTUAL | February 2021

,

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia | Antimicrob Agents Chemother | February 2021 | Vol 65, Issue 3

,

SCCM

VIRTUAL | January 2021

,

Rezafungin: a novel antifungal for the treatment of invasive candidiasis | Future Microbiol | January 2021 | Vol 16, Issue 1

,

ESWI

Keynote Lecture| December 2020

,

ESWI

VIRTUAL | December 2020

,

ESICM LIVES

VIRTUAL | December 2020

,

IDWeek

VIRTUAL | October 2020

,

IDWeek

VIRTUAL | October 2020

,

ACCP

VIRTUAL | October 2020

,

Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis – The STRIVE Trial | Clin Infect Dis | September 2020 | Corrected Proof

,

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida SpeciesJ Fungi | August 2020 | Vol 6, Issue 3

,

ASM Microbe

Accepted Abstracts | June 2020 (conference cancelled)

,

ECCMID

Abstract Book | April 2020

,

ECCMID

Abstract Book | April 2020

,

Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4

,

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018) | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4

,
,

ASH

Orlando, Florida | December 2019

,

Rezafungin Treatment in Mouse Models of Invasive-Candidiasis and Aspergillosis: Insights on the PK/PD Pharmacometrics of Rezafungin Efficacy | Pharmacol Res Perspect | December 2019 | Vol 7, Issue 6

,

Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects | Clin Pharmacol Drug Dev | December 2019 | Vol 9, Issue 4

,

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae | J Antimicrob Chemother | December 2019 | Vol 74, Issue 12

,

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model | Antimicrob Agents Chemother | November 2019 | Vol 63, Issue 11

,

IDWeek

Washington, D.C. | October 2019

,

IDWeek

Washington, D.C. | October 2019

,

TIMM

Nice, France | October 2019

,

RICAI

Paris, France | December 2019

,

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatusAntimicrob Agents Chemother | October 2019 | Vol 63, Issue 10

,

Options X

Singapore | August 2019

,

ASM Microbe

San Francisco, CA | June 2019

,

ASM Microbe

San Francisco, CA | June 2019

,

ECCMID

Amsterdam | April 2019

,

ECCMID

Amsterdam, The Netherlands | April 2019

,

EBMT

Frankfurt, Germany | March 2019

,

TCT

Houston, TX | February 2019

,

ASH

San Diego, CA | December 2018

,

Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive-Candidiasis Model Antimicrob Agents Chemother | November 2018 | Vol 62, Issue 11

,

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species November 2018 | Vol 73, Issue 11

,

IDWeek

San Francisco, CA | October 2018

,

HTIDE

Venice, Italy | October 2018

,

Rezafungin (CD101), a Next Generation Echinocandin. a Systematic Literature Review and Assessment of Possible Place in Therapy J Glob Antimicrob Resist | September 2018 | Vol 14

,

EUCAST reference testing of rezafungin susceptibility: impact of choice of plastic plates Antimicrob Agents Chemother | September 2019 | Vol 63, Issue 9

,

Evaluation of the Efficacy of Rezafungin, a Novel Echinocandin, in the Treatment of Disseminated Candida auris Infection Using an Immunocompromised Mouse Model J Antimicrob Chemother | August 2018 | Vol 73, Issue 8

,

ISHAM Congress

Amsterdam, The Netherlands | July 2018

,

ASM Microbe

Atlanta, GA | June 2018

,

ICHS Symposium

Athens, Greece | June 2018

,

Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy Blood Purif | June 2018 | Vol 46, Issue 3

,

Overcoming the Resistance Hurdle: PK-PD Target Attainment Analyses of Rezafungin (CD101) for Candida albicans and Candida glabrata Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6

,

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6

,

ECCMID

Madrid, Spain | April 2018

,

AKI & CRRT

San Diego, CA | March 2018

,

EBMT

Lisbon, Portugal | March 2018

,

Activity of CD101, a Long-Acting Echinocandin, Against Clinical Isolates of Candida auris Diag Microbiol Infect Dis | March 2018 | Vol 90, Issue 3

,

BMT Tandem

Salt Lake City, UT | February 2018

,

Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2

,

CD101, a Novel Echinocandin Possesses Potent Anti -Biofilm Activity Against Early and Mature Candida albicans Biofilms Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2

,

The Future of Echinocandin Therapy J Antimicrob Chemother | January 2018 | Vol 73, Issue Suppl 1

,

In Vitro Potency and Fungicidal Activity of CD101, a Novel Echinocandin, Against Recent Clinical Isolates of Candida Spp. Diag Microbiol Infect Dis | November 2017 | Volume 89, Issue 3

,

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters Antimicrob Agents Chemother | November 2017 | Vol 61, Issue 11

,

IDWeek

San Diego, CA | October 2017

,

TIMM

Belgrade, Serbia | October 2017

,

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model Antimicrob Agents Chemother | October 2017 | Vol 61, Issue 10

,

CD101, a Long-Acting Echinocandin, and Comparator Antifungal Agents Tested Against a Global Collection of Invasive Fungal Isolates in the SENTRY 2015 Antifungal Surveillance Program Int J Antimicrob Agents | September 2017 | Vol 50, Issue 3

,

ASM Microbe

New Orleans, LA | June 2017

,

EHA

Madrid, Spain | June 2017

,

ECCMID

Vienna, Austria | April 2017

,

Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species Antimicrob Agents Chemother | April 2017 | Volume 61, Issue 4

,

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin With Distinctive Pharmacokinetic Properties  Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2

,

CD101, a Novel Echinocandin With Exceptional Stability Properties and Enhanced Aqueous Solubility J Antibiotics | February 2017 | Volume 70, Issue 2

,

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested Against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY (2014) Antifungal Surveillance Program Antimicrob Agents Chemother | March 2017 | Volume 61, Issue 3

,

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults  Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2

,

ASH

San Diego, CA | December 2016

,

ICHS-Infocus

Santiago, Chile | November 2016

,

Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin Antimicrob Agents Chemother | November 2016 | Volume 60, Issue 11

,

ACCP

Hollywood, FL | October 2016

,

IDWeek

New Orleans, LA | October 2016

,

Activity of a Long-Acting Echinocandin, CD101, Determined Using CLSI and EUCAST Reference Methods, Against Candida and Aspergillus Spp., Including Echinocandin- and Azole-Resistant Isolates J Antimicrob Chemother | October 2016 | Volume 71, Issue 10

,

CD101: a Novel Long-Acting Echinocandin Cell Microbio | September 2016 | Volume 18, Issue 9

,

Characterization of in Vitro Resistance Development to the Novel Echinocandin, CD101, in Candida Species Antimicrob Agents Chemother | September 2016 | Volume 60, Issue 10

,

ASM Microbe

Boston, MA | June 2016

,

ECCMID

Amsterdam, Netherlands | April 2016

,

Advances Against Aspergillosis

Manchester, UK | March 2016

,

ICAAC/ICC

San Diego, CA | September 2015

,

Advances Against Aspergillosos

Lisbon, Portugal | February 2018

,

ICAAC

Washington, DC | September 2014

,